Biocodex is a family-owned multinational pharmaceutical company founded in France in 1953. The initial focus of the company was gastroenterology, featuring a unique probiotic: Saccharomyces boulardii CNCM I-745®, the first probiotic drug to have a positive effect on intestinal microbiota.
The history of Biocodex started in 1923 with the discovery of the yeast Saccharomyces boulardii CNCM I-745® in Indochina by Henri Boulard. In 1953, the Hublot and Vallet families acquired the rights to Henri Boulard’s yeast strain and fermentation process launching Biocodex.
Today, Biocodex has transformed itself, expanding its development around three pillars, microbiota, women’s heath, and orphan drugs. They are represented by 20 different subsidiaries across the globe and over 1,500 employees.
Canada subsidiary was created in 2013 and has since offered 8 years of gut support to the Canadians, commercializing Biocodex flagship probiotic under the name “Florastor” as a natural health product.
Want to know more?
Biocodex develops, manufactures and distributes world-class pharmaceutical products and health solutions for patients in more than 120 countries. Focusing on three main pillars (microbiota mission, orphan drugs and women’s health), we combine in house R&D and scientific partnerships, production expertise, and investments in start-ups to remain at the forefront of innovation and quality.
Biocodex is a family-owned company founded more than 60 years ago to market the world's first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Biocodex has since expanded its expertise in gut microbiota, evolving from French pioneer to an international player in the microbiota realm.